Biocryst Pharmaceuticals reported $-51199000 in EBITDA for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alexion Pharmaceuticals ALXN:US $ 892.3M 186.4M
Alnylam Pharmaceuticals ALNY:US $ -134.35M 39.3M
Chemocentryx CCXI:US $ -37.74M 8.52M
Daiichi Sankyo 4568:JP Y 60453M 71607M
Gilead Sciences GILD:US $ 2816M 669M
Glaxosmithkline GSK:US $ 2626M 584M
GlaxoSmithKline GSK:LN 2626M 584M
Intra Cellular Therapies ITCI:US $ -69.02M 15.92M
Karyopharm Therapeutics KPTI:US $ -48819000 3.32M
Mirati Therapeutics MRTX:US $ -163.78M 31.65M
Neurocrine Biosciences NBIX:US $ 70.4M 36.4M
Novavax NVAX:US $ -343.42M 137.1M
Ptc Therapeutics PTCT:US $ -83.51M 1.05M
Regeneron Pharmaceuticals REGN:US $ 3418.3M 2238.2M
Sarepta Therapeutics SRPT:US $ -159.13M 26.19M
Ultragenyx Pharmaceutical RARE:US $ -79.66M 23.55M
Vertex Pharmaceuticals VRTX:US $ -5.12M 917.88M
YTE INCY:US $ 169.77M 41.12M
Zogenix ZGNX:US $ -53.07M 3.63M